Stocktoria
NEKTAR THERAPEUTICS NKTR
NEKTAR THERAPEUTICS (NKTR) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $55.2M at a -297.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NKTR | NEKTAR THERAPEUTICS | 1/9 | — | — | -43.9% |
| AGIO | AGIOS PHARMACEUTICALS, INC. | 2/9 | 12.52 | — | +48% |
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
About NEKTAR THERAPEUTICS
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
FAQ
Is NKTR financially healthy?
NEKTAR THERAPEUTICS's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does NKTR pay a dividend?
No, NEKTAR THERAPEUTICS does not currently pay a dividend.
How profitable is NKTR?
In FY2025, NEKTAR THERAPEUTICS had a net margin of -297.1% and a return on equity of -182.6%.
What is the analyst price target for NKTR?
The average Wall-Street price target for NEKTAR THERAPEUTICS is $153.25, about 101.6% above the recent price, from 8 analysts (consensus: strong buy).
Is NKTR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEKTAR THERAPEUTICS: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.